Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that dMMR status confers therapeutic sensitivity to Pembrolizumab in patients with Colorectal Adenocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.